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Abstract
Background: Risk predicting models have been applied in idiopathic pulmonary fibrosis (IPF), but still not validated
in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). The purpose of this study was to
test the suitability of three prediction models as well as individual lung function and demographic factors for
evaluating the prognosis of RA-ILD patients.
Methods: Clinical and radiological data of 59 RA-ILD patients was re-assessed. GAP (gender, age, physiologic variables)
and the modified interstitial lung disease (ILD)-GAP as well as the composite physiologic indexes (CPI) were tested for
predicting mortality using the goodness-of-fit test and Cox model. Potential predictors of mortality were also sought
from single lung function parameters and clinical characteristics.
Results: The median survival was 152 and 61 months in GAP / ILD-GAP stages I and II (p = 0.017). Both GAP and ILD-GAP
models accurately estimated 1-year, 2-year and 3-year mortality. CPI (p = 0.025), GAP (p = 0.008) and ILD-GAP (p = 0.028)
scores, age (p = 0.002), baseline diffusion capacity to carbon monoxide (DLCO) (p = 0.014) and hospitalization due to
respiratory reasons (p = 0.039), were significant predictors of mortality in the univariate analysis, whereas forced vital
capacity (FVC) was not predictive. CPI score (HR 1.03, p = 0.018) and baseline DLCO (HR 0.97, p= 0.011) remained
significant predictors of mortality after adjusting for age.
Conclusions: GAP and ILD-GAP are applicable for evaluating the risk of death of patients with RA-ILD in a similar manner
as in those with IPF. Baseline DLCO and CPI score also predicted survival.
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Background
The course of disease in interstitial lung diseases (ILD), in-
cluding rheumatoid arthritis-associated interstitial lung
disease (RA-ILD), is known to be highly variable. Predict-
ing the survival of an individual patient with ILD is
challenging [1]. Several factors have, however, been pro-
posed to predict disease progression and survival i.e.
physiological, radiological and histopathological character-
istics, as well as demographic variables such as age and
gender [2]. Some factors reflecting the severity of the
rheumatoid arthritis (RA) have also been associated with
worse survival, e.g. baseline pain [3], disease activity score
[4] and health-assessment questionnaire score [3, 5].
There are now several indexes which combine single
factors into a multifaceted scoring system and these have
proved beneficial in estimating prognosis. These models
have, however, focused mainly on idiopathic pulmonary
fibrosis (IPF) and some of the earliest models were ra-
ther cumbersome and therefore never achieved any
widespread clinical acceptance [6]. A composite
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physiologic index (CPI) displayed some important ad-
vantages over the older models, since it contained only
pulmonary function test (PFT) and gas transfer values
but omitted radiological scoring or exercise testing [7].
The subsequently developed GAP model combines gen-
der (G), age (A) and two lung physiology variables (P),
i.e. forced vital capacity (FVC) and diffusion capacity to
carbon monoxide (DLCO), into a multidimensional
index and staging system with three stages (I-III) pro-
posing 1-year mortality of 6, 16 and 39% [8]. This GAP
model has also been utilized in the prognosis of other
chronic ILDs in addition to IPF. The modified model
was named as ILD-GAP, with the assumption that pa-
tients with connective tissue disease-related ILDs (CTD-
ILD) enjoyed a better survival than those suffering from
IPF [9]. The survival of patients with RA-ILD has been
shown to be as poor as in IPF patients [10], at least in
those cases with usual interstitial pneumonia (UIP)
which is the most common subtype in RA-ILD and un-
like the situation in the other CTD-ILDs [11]. Thus,
since it is mainly UIP-typed, RA-ILD follows a distinct-
ive disease course from the other CTD-ILDs and it re-
mains unclear which of the prognostic indexes, GAP or
ILD-GAP, would be better suited for RA-ILD. There are
some reports of the benefits of using the CPI score,
GAP and ILD-GAP staging systems in patients with IPF
and systemic sclerosis-associated ILD [12–14]. However,
as far as we are aware, neither CPI nor GAP/ILD-GAP
have been previously investigated in patients with RA-
ILD, if one excludes the subjects in the original ILD-
GAP publication, which did include some RA-ILD
patients in their CTD-ILD/idiopathic nonspecific inter-
stitial pneumonia (iNSIP) group of 326 patients.
The aims of this study were to investigate the applic-
ability of CPI, GAP and ILD-GAP scores for predicting
the prognosis of the patients with RA-ILD treated in
Kuopio University Hospital (KUH), in Eastern Finland,
during the years 2000–2014. In addition, we examined
the association between individual PFT and demographic
factors with the survival of the patients.
Methods
Data sources and search
The study cohort consists of patients treated in the
KUH pulmonology in-patient or out-patient clinic be-
tween 1.1.2000 and 31.12.2014. The patients were
identified from the database of KUH using two Inter-
national Classification of Diseases (ICD-10) codes,
namely J84.X and M05.X/M06.X (Fig. 1). These
searches resulted in identification of 1047 patients,
and their patient records were evaluated in order to
identify those patients suffering from clinically rele-
vant RA-ILD. The search process and clinical charac-
teristics of the patients are thoroughly described in
our previous study [15]. Shortly, all patients without a
certain diagnosis of RA or without HRCT confirmed
ILD were excluded, as were those with mixed CTD-
like symptoms. Atypical cases were debated by a
multidisciplinary discussion. Finally, 59 radiologically
diagnosed RA-ILD patients were identified to be stud-
ied in detail and classified adopting the year 2013 IIP
classification [16]. The radiological RA-UIP criteria
Fig. 1 Study protocol. Flowchart of patient enrollment into the study showing the subdivision into the different GAP / ILD-GAP groups. ILD = interstitial
lung disease; RA = rheumatoid arthritis; HRCT = high-resolution computed tomography; RA-ILD = rheumatoid arthritis-associated interstitial lung disease;
UIP = usual interstitial pneumonia; NSIP = nonspecific interstitial pneumonia; OP = organizing pneumonia; DAD = diffuse alveolar damage;
MDD =multidisciplinary discussion; GAP = gender, age, physiologic variables
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that were applied were those for the diagnosis of IPF
[17] when 32 (54.2%) of the patients had a radio-
logical definite UIP pattern [15]. After a multidiscip-
linary discussion, two additional patients with a
slightly upper- or mid-lung predominated distribution
where included in the RA-UIP group (35/59.3%),
whereas patients with a possible UIP pattern are not
included in the UIP group but instead categorized in
the unclassified group. In addition to RA-UIP pa-
tients, there were eight RA-NSIP (13.6%), seven RA-
OP (11.9%), one RA-DAD (1.7%) and eight unclassi-
fied patients (13.6%) as previously described [15].
Gathering of demographic information
Clinical information was gathered from the patient
records of KUH, primary health care centers and other
hospitals using a specially designed form. Demographic
data and the lifelong medication history for RA were
gathered comprehensively. The number of hospitaliza-
tions was also obtained and further categorized into
either mainly respiratory (i.e. infections, suspected drug
reactions and suspected acute exacerbations of ILD) or
cardiac problems as presented previously [15]. The
results of PFT, such as spirometry including FVC and
forced expiratory volume (FEV1), as well as DLCO were
gathered at baseline and, when available, during the
follow-up annually, including also the most recent avail-
able results. The reference values of Viljanen were used
when assessing PFT results [18].
Staging systems
Composite physiologic index (CPI) was calculated using
the formula [7]: CPI = 91 – (0.65 × DLCO % predicted)
– (0.53 × FVC % predicted) + (0.34 × FEV1 % predicted).
GAP / ILD-GAP score was calculated by gender, age,
FVC % predicted and DLCO % predicted and patients
divided to GAP / ILD-GAP stages I and II as previously
described [8, 9]. There were no stage III (or IV in ILD-
GAP) patients in our study material.
Statistical analysis
The distribution of the continuous variables was verified
with the Shapiro-Wilk test. If there was a normal distri-
bution, the independent T-test was used to compare
continuous variables, otherwise the Mann-Whitney U-
test was used. The chi-squared test or Fisher test, when
appropriate, was used for comparison of categorical vari-
ables. Gender, smoking habits, laboratory results, use of
medications, comorbidities, use of oxygen and the num-
bers of observed deaths were calculated as percentages.
Age at the time of RA-ILD diagnosis or death, lung
function results and hospitalizations were expressed as
mean ± SD. Survival curves were estimated using the
Kaplan-Meier method and differences in survival time
between GAP / ILD-GAP stages I and II were calculated
by the log-rank test. Survival results are expressed as
median (95% confidence interval). The observed 1-, 2-,
and 3-year mortality rates were calculated and these
were supplemented with an estimate of the confidence
interval by using the Wilson score. Next, the observed
mortality and the risk of death predicted by the GAP /
ILD-GAP model were compared using Hosmer-
Lemeshow goodness-of fit-test. Finally, Cox regression
analysis was used to identify factors that predicted
mortality.
P-values <0.05 were considered significant. All data
was analyzed using IBM Statistics SPSS software,
version 21.0.
Results
Patient characteristics, lung functions and CPI score
The mean RA duration at the point when ILD was diag-
nosed was 15.6 ± 12.2 years, ranging from 0 to 52 years.
The female–male ratio was 1:1.27. A substantial number
(39.7%) of the patients had never smoked. The mean
CPI score of all RA-ILD patients was 27.2 ± 14.4 (range
2.4–61.3) (Table 1).
The detailed data of the lung function test results is
shown in Table 1. Over half (30/55.6%) of the patients
had a normal FVC at the time of RA-ILD diagnosis.
Twenty-five (49%) of the patients had a normal baseline
DLCO and furthermore, in 17 patients (33.3%) both
FVC and DLCO were normal (Table 1). The clearest de-
cline of all PFT was observed in DLCO, the final mean
was 61.1 ± 21.4 (range 13–105).




Normal (>80%) 30 (55.6)
Declined (50–80%) 23 (42.6)
Severely declined (<50%) 1 (1.9)
Normal FEV1 (>80%) 29 (53.7)
Normal FEV1/FVC (>88%) 44 (81.5)
Normal DLCO (>74%) 25 (49.0)
Normal FVC + Normal DLCO 17 (33.3)
Mean FVC 84.76 ± 16.9
Mean FEV1 81.76 ± 16.3
Mean FEV- % 97.59 ± 12.4
Mean DLCO 71.12 ± 18.1
CPI score 27.2 ± 14.4
Data shown as number (%), or mean ± SD. FVC, FEV1 and FEV1/FVC results are
missing from five patients. DLCO results are missing from eight patients. Both
FVC and DLCO results were available for 51 patients
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GAP and ILD-GAP
There was all the necessary data available from 51
patients to allow the calculation of GAP and ILD-
GAP scores. The majority of the subjects i.e. 76.5%
(n = 39) belonged to stage I with the remaining 23.5%
categorized into the stage II group. There were no
patients in stage III. The same patients who were
categorized as GAP I constituted the ILD-GAP I
group and the patients in GAP II group, were also the pa-
tients with ILD-GAP II (Fig. 1). GAP / ILD-GAP I and II
differed significantly with respect to several clinical
findings and lung function e.g. age (p = 0.024), gender
(p < 0.001), smoking status (p = 0.033), baseline FVC
(p < 0.001), FEV1 (p = 0.013) and DLCO (p < 0.001)
(Table 2). The use of methotrexate was also more
common in stage I patients than in their stage II
counterparts (64.1% vs. 33.3%), although this finding
did not reach statistical significance (p = 0.060). No
statistically significant differences were observed in
RA serology or comorbidities. The mean CPI score
was 22.4 ± 12.2 in GAP / ILD-GAP I and 42.8 ± 9.3 in
stage II (p < 0.001). Patients with the UIP pattern in
HRCT (RA-UIP) divided almost equally in both stages
(64% in stage I, 50% in stage II, p = 0.502).
The follow-up outcomes
No statistically significant differences were observed
between GAP / ILD-GAP I and II with regard to hos-
pital admissions either due to respiratory or cardio-
logic reasons (Table 3). The use of oxygen was also
similar in both groups (p = 1.000). Eighteen patients
(46.2%) died due to any cause in the GAP / ILD-GAP
stage I whereas there were 9 deceased patients
(75.0%) in the stage II group (p = 0.080). The ob-
served cumulative mortality rates at 1, 2 and 3 years
were 7.0, 16.7 and 22.6%, respectively. The observed
1-year, 2-year or 3-year mortality did not differ sig-
nificantly according to GAP / ILD-GAP stage.
Survival and validation of the GAP and ILD-GAP models
The median survival was 152 months in stage I but only
61 months in stage II (p = 0.017) (Fig. 2). There were no
apparent differences in the observed and predicted risk
of death (Table 4). Both prediction models fitted the
Wilson score confidence interval of the observed
mortality.
The observed mortality and the risk of death predicted
by these models were compared using the Hosmer-
Lemeshow goodness-of-fit test (Figs. 3 and 4). Both GAP
and ILD-GAP indexes predicted 1-year, 2-year and 3-
year mortality accurately (all p-values were > 0.05). The
ILD-GAP index was more accurate at predicting 1-year
mortality (p = 0.552) than the GAP index (p = 0.254).
However, the GAP index was slightly more accurate at
predicting 2-year (p = 0.261) and 3-year (p = 0.595)
mortality than the ILD-GAP index (2-year p = 0.139,
3-year p = 0.357).
Predictors of mortality
GAP and ILD-GAP indexes, as well as the CPI score
were all significant predictors of mortality when assessed
with the univariate Cox model. The hazard ratio (HR) of
GAP was 1.56 (95% CI: 1.15–2.11; p = 0.004), that of
ILD-GAP 1.51 (95% CI: 1.05–2.18; p = 0.026) and of CPI
1.03 (95% CI 1.01–1.06; p = 0.015) (Table 5).
Age at diagnosis (HR 1.06, 95% CI 1.02–1.10, p = 0.002),
baseline DLCO (HR 0.98, 95% CI 0.96–1.00, p = 0.014)
and hospitalization due to respiratory reasons (HR 1.12,
1.01–1.26, p = 0.039) were also significant predictors of
Table 2 Baseline characteristics of the patients with RA-ILD





Age (y) 63.4 ± 11.6 71.5 ± 5.5 0.024
Age at death (y) 72.6 ± 9.9 76.6 ± 5.6 0.266
Male sex 16 (41.0) 12 (100.0) <0.001
UIP pattern 25 (64.1) 6 (50.0) 0.502
Smoking*
Never 19 (48.7) 1 (9.1) 0.033a
Ex-smoker 15 (38.5) 7 (63.6)
Current smoker 5 (12.8) 3 (27.3)
Serology
Positive RF** 29 (78.4) 11 (91.7) 0.420a
Positive
ANA***
4 (14.3) 2 (22.2) 0.620a
Medications
Steroids 36 (92.3) 10 (83.3) 0.580a
MTX 25 (64.1) 4 (33.3) 0.060
Biological
drugs
11 (28.2) 1 (8.3) 0.250a
Lung functions
FVC % pred 89.8 ± 15.8 72.6 ± 8.5 <0.001
FEV1 % pred 85.1 ± 16.3 72.3 ± 8.9 0.013
DLCO % pred 76.8 ± 15.6 52.8 ± 12.7 <0.001
RA duration (y) 15.7 ± 10.6 14.8 ± 14.4 0.808
CPI points 22.4 ± 12.2 42.8 ± 9.3 <0.001
For eight patients there was no lung function data and therefore the GAP /
ILD-GAP score could not be calculated
RF rheumatoid factor, ANA antinuclear antibodies, MTX methotrexate, FVC
forced vital capacity, DLCO diffusing capacity of the lung for carbon
monoxide, % pred percentage of the predicted value, CPI composite
physiologic index
*Data missing from one stage II patient
**Data missing from two stage I patients with positive anti-cyclic citrullinated
peptide antibodies
***Data missing from 14 patients (11 stage I, 3 stage II)
aFisher test
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mortality in the univariate model, but neither FVC nor
hospitalization due to cardiologic reasons was predictive.
The UIP pattern was not an independent risk factor in this
cohort, neither was smoking nor male gender. The use of
either methotrexate or oxygen did not reach statistical sig-
nificance as risk factors for death (Table 5).
Age adjusted predictors of mortality
After adjusting for age, CPI score and baseline DLCO
remained as significant predictors of mortality. For
every increased CPI point, the mortality risk increased
by 3% (HR 1.03, 95% CI 1.01–1.06, p = 0.014) and for
every increased DLCO level, the risk of death dimin-
ished by 3% (HR 0.97, 95% CI 0.95–0.99, p = 0.011).
The rest of the factors that were detected in the uni-
variate Cox model lost their statistical significance
after adjustment for age (Table 6).
Discussion
In this present study, we applied the GAP and the
ILD-GAP scores in a cohort consisting of 59 patients
with RA-ILD subdivided into GAP / ILD-GAP stages
I and II. Both GAP systems showed significant differ-
ences in age, gender, FVC, FEV1, DLCO and CPI-
score, which is understandable since GAP / ILD-GAP
are mainly composed of the above-mentioned compo-
nents. The median survival of the patients categorized
into GAP / ILD-GAP II groups was significantly
shorter than those in the GAP / ILD-GAP I group.
The CPI score was an independent predictor of mor-
tality similarly as GAP / ILD-GAP scores, age, base-
line DLCO and hospitalization due respiratory
reasons. However, after adjustment for age, only the
CPI score and DLCO remained as statistically signifi-
cant predictors. In addition to the Cox model, the
applicability of GAP and ILD-GAP was tested using
Table 3 Course of disease and survival of the patients with RA-ILD
GAP / ILD-GAP stage I (n = 39/76.5%) GAP / ILD-GAP stage II (n = 12/23.5%) P-value
Number of deaths 18 (46.2) 9 (75.0) 0.080
Hospitalization due to respiratory illness 1.0 ± 1.4 (0–5) 1.6 ± 3.1 (0–11) 0.343
Hospitalization due to cardiac illness 0.5 ± 1.0 (0–5) 1.0 ± 1.8 (0–4) 0.366
Use of Oxygen 6 (15.4) 1 (8.3) 1.000a
Median survival 152.0 (93.0–211.0) 61.0 (25.2–96.8) 0.017
Observed 1-y deaths* 0 (0.0) 1 (8.3) 0.245
Observed 2-y deaths** 5 (14.3) 1 (9.1) 1.000
Observed 3-y deaths*** 6 (17.6) 3 (27.3) 0.666
Categorical variables are compared using the Fisher test when marked a, otherwise χ2-test. Hospitalizations are compared using the Mann-Whitney U-test
*Data missing from two stage I patients
**Data missing from four stage I patients and one Stage II patient
*** Data missing from five Stage I patients and one Stage II patient
Fig. 2 Comparison of the survival curves of the RA-ILD patients
categorized into either GAP / ILD-GAP stage I or II. The survival was
significantly worse in GAP / ILD-GAP stage II (p = 0.017, Log Rank)









Stage I 0.0 (0.0–9.4) 5.6 3.1
Stage II 8.3 (1.5–35.4) 16.2 8.8
2-Y mortality
Stage I 14.3 (6.3–29.4) 10.9 6.6
Stage II 9.1 (1.6–37.7) 29.9 18.0
3-Y mortality
Stage I 17.6 (8.3–33.5) 16.3 10.2
Stage II 27.3 (9.7–56.6) 42.1 26.9
% (95% CI calculated by Wilson score)
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two different statistical methods. Both the GAP and
the ILD-GAP methods provided relatively good esti-
mates of mortality. Interestingly, the GAP index was
more accurate at predicting 2-year and 3-year mortal-
ity, whereas ILD-GAP predicted 1-year mortality more
precisely.
To our knowledge, only a few previous studies have
investigated GAP or ILD-GAP scores in patients with
CTD-ILD but some analyses of IPF have been published.
In Korean IPF patients, the GAP score produced accur-
ate 1-year, but not 3-year, mortality estimates [13]. In
another study of IPF patients, the GAP staging was
found to be useful for evaluating the IPF severity, reveal-
ing statistically significant differences in survival in dif-
ferent GAP stages [12]. On the other hand, the ILD-
GAP index displayed poor applicability for the predicted
1-year mortality in systemic sclerosis-associated ILD
patients [14].
In this study, the observed 1-year mortality was 0 in
stage I and 8.3% in stage II patients. Predicted 1-year
mortality using the ILD-GAP was 3.1 and 8.8% in stages
I and II, respectively. Thus, the accuracy of ILD-GAP
was good at predicting 1-year mortality but the observed
2-year mortality in stage I patients was much higher
than predicted by the ILD-GAP model i.e. the GAP
model was more accurate at that time point. The ILD-
GAP prediction also underestimated the 3-year mortality
of stage I patients, which was observed to be 17.6 and
therefore was even slightly higher than the value pre-
dicted by GAP. Both of the indexes, however, fitted
within the confidence interval of the observed mortality.
Since the accuracy of GAP and ILD-GAP in predicting
annual mortality in our study was variable at different
points, it remains unclear whether the GAP or ILD-GAP
index is better suited in predicting mortality of patients
with RA-ILD. The ILD-GAP was originally developed in
a study protocol including all kinds of ILDs without tak-
ing into account the fact that the prognosis and course
of disease is variable in the different types CTD-ILDs
[19, 20]. In some earlier studies, the survival of RA-ILD
Fig. 3 The Hosmer-Lemeshow statistic tests show that the predicted and observed risks do not differ significantly (p > 0.05). The x-axis shows the
1-y, 2-y and 3-y risk of mortality as predicted by the GAP staging system and the y-axis shows the observed risk. In every figure, stage I is on the
left side and stage II on the right side. The vertical lines represent the confidence interval of the observed mortality rate
Fig. 4 The Hosmer-Lemeshow statistic tests show that the predicted and observed risks do not differ significantly (p > 0.05). The x-axis shows the
1-y, 2-y and 3-y risk of mortality as predicted by the ILD-GAP staging system and the y-axis shows the observed risk. In every figure, stage I is on
the left side and stage II on the right side. The vertical lines represent the confidence interval of the observed mortality rate
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patients has been reported as being as poor as in IPF
[3, 21], whereas that of other types of CTD-ILD has
appeared to be better [10, 19, 22]. Furthermore, vari-
ous radiological or histological patterns in certain
CTD may behave differently, e.g. patients with RA-
UIP have been shown to have a shorter survival than
those with other CTD-ILDs [23, 24]. Therefore, it
can be debated whether the ILD-GAP, which is
merely a simple subtraction from the GAP score as-
suming a better survival in CTD-ILDs, is valid in all
CTD-ILDs.
The significance of PFT has been widely recognized
when evaluating ILD severity and the risk of death. In fi-
brotic subtypes of IIPs, it has been postulated that pul-
monary physiology is an even stronger predictor of
survival than the histopathologic pattern [25] and that in
patients with IPF, changes in FVC % predicted and
DLCO % predicted have been shown to associate with
mortality [26, 27]. Moreover, a prospective follow-up
study of 29 RA-ILD patients demonstrated that in over
30% of cases, a degree of radiological progression was
observed, and this progression was strongly associated
with a reduced DLCO [28].
In a recent retrospective study of 48 biopsy-confirmed
RA-ILD patients, the baseline DLCO was detected as an
important risk factor for death in a univariate model
similarly as found here [29]. In that particular study,
however, DLCO lost its statistical significance in the
multivariate model, when only age and the presence of
fibrosis remained significant [29]. Another study of 82
RA-ILD patients diagnosed without biopsy found that
baseline DLCO was associated with survival in the bi-
variate analysis, and DLCO remained statistically signifi-
cant also in the multivariate analysis [30]. In a very
recent study, a relatively large cohort of 137 RA-ILD pa-
tients was retrospectively evaluated, with univariate,
multivariate and also longitudinal methods being used to
analyze the predictors of mortality [31]. In that study a
baseline DLCO value of 10% lower than the mean value
and DLCO decline of 10% or more at any time after
baseline were identified as significant predictors of mor-
tality [31]. Furthermore, in the study of Song et al. [32]
which examined 84 RA-UIP patients, the hazard ratio of
baseline DLCO did not reach statistical significance, but
the change of DLCO was significant in both univariate
and multivariate models. Unfortunately, we were not
able to investigate the change in DLCO over time be-
cause of missing follow-up data due to the retrospective
nature of our study protocol. In addition, multivariate
models could not be applied because of the small num-
ber of patients in our study. However, we observed that
the significant positive result of DLCO in univariate ana-
lysis remained after adjusting for age. Overall, the results
of DLCO in our study support the previous findings of
the suitability of DLCO in the disease severity evaluation
of RA-ILD.
Baseline FVC was not found to be an independent
predictor of mortality in our study, a finding which is at
odds with some previous studies. A recent study showed
that the lower baseline FVC (10% or more under mean
value) and a 10% decline in FVC were both associated
with an increased death hazard in various multivariate
models [31]. Furthermore, another investigation demon-
strated that the baseline FVC, as well as the FVC change
over time, were significant predictors of mortality in pa-
tients with RA-UIP [32]. There may be two possible ex-
planations why the significance of FVC in our study
differs from these other publications. Firstly, in our
study, the mean baseline FVC was relatively high, i.e.
84.8, being within the normal limits in the majority of
the patients whereas the corresponding value in the
study of Solomon et al. was 69.3, and that from Song et
al. was 75.1 [31, 32]. Our finding refers that the patients
had been diagnosed earlier with more preserved lung
functions. Secondly, our study includes 59 patients, thus
being relatively small, compared to those other studies
of 84 and 137 patients. On the other hand, the results of
Table 5 Prognostic factors for survival in patients with RA-ILD
using a univariate Cox model
Hazard ratio 95% CI P- value
Age at diagnosis 1.06 1.02–1.10 0.002
Male sex 1.49 0.73–3.05 NS
Smoking 0.83 0.41–1.67 NS
FVC % pred 0.98 0.96–1.01 NS
DLCO % pred 0.98 0.96–1.00 0.014
RA duration 0.99 0.96–1.03 NS
UIP pattern in HRCT 0.77 0.36–1.64 NS
Positive RF 0.69 0.24–1.98 NS
MTX 1.20 0.59–2.42 NS
Use of oxygen 1.74 0.74–4.09 NS
Resp. hospitalization 1.12 1.01–1.26 0.039
Card. hospitalization 1.13 0.87–1.46 NS
CPI- points 1.03 1.01–1.06 0.015
GAP score 1.56 1.15–2.11 0.004
ILD-GAP score 1.51 1.05–2.18 0.026
Table 6 Prognostic factors for survival after adjustment for age
Hazard ratio 95% CI P- value
DLCO % pred 0.97 0.95–0.99 0.011
Resp. hospitalization 1.11 0.99–1.26 0.084
CPI- points 1.03 1.01–1.06 0.014
GAP score 1.37 0.96–1.94 0.083
ILD-GAP score 1.32 0.90–1.95 0.158
Nurmi et al. BMC Pulmonary Medicine  (2017) 17:16 Page 7 of 9
the study of Kim et al., which included 84 patients with
RA-ILD who had lower mean baseline of FVC values
than in our study (66 ± 25 in RA-UIP, 70 ± 20 in non-
UIP) did not actually find FVC to be a predictor of
death, i.e. similar to our results [23]. Even though FVC
alone was not a strong predictor of mortality in our
study, it is one factor included in CPI and GAP / ILD-
GAP scores, all of which showed significant positive re-
sults in our univariate analyses. Our finding supports
that the use of multifaceted scoring systems for evaluat-
ing the prognosis of the patients with RA-ILD may be
beneficial.
Conclusions
In conclusion, GAP, ILD-GAP and CPI were all func-
tional when predicting survival of patients with RA-ILD.
In addition, baseline DLCO was associated with length
of remaining lifetime. In clinical practice, reliable
methods are needed for evaluating the progression of
the disease and predicting an individual’s life expectancy
and predictive scoring systems could be helpful in every-
day work and in patient counselling. Hopefully in the fu-
ture, more disease-specific methods can be developed
and validated, although this would require additional
multicenter studies.
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